




SARC SEMIANNUAL MEETING BEFORE ASCO

FRIDAY, MAY 29, 2026 ♦ 7:30 AM-12 NOON CENTRAL

Northwestern Memorial Hospital, Feinberg Conference Center 3rd Floor 251 E. Huron Street, Chicago, IL, USA

7:30-8:55 am	Breakfast & Networking	Feinberg Krumlovsky Atrium
9:00-9:10 am	Welcome	Feinberg ABCD Conference Room
	<i>Opening Remarks</i>	Steven Young (SARC President & CEO)
9:10-10:30 am	Session 1: Precision Delivery in Sarcoma: Targets, Modalities, Clinical Contexts	Presenters (bolded)
	<i>Introduction</i>	Jonathan Fletcher MD (SARC CSO; BWH)
	<i>Session Chair</i>	Breelyn Wilky MD (CU Anschutz)
	○ ADCs for Osteosarcoma	Richard Gorlick MD (MDACC)
	○ Integrating radiopharmaceuticals in the combined modality treatment of patients with sarcoma	Zachary Morris MD PhD (U. Wisconsin)
	○ Bispecific Antibodies for Alpha Therapy	Nai-Kong V Cheung MD PhD (MSKCC)
	<i>Discussions: Panel & Audience</i>	
10:30-11:40 am	Session 2: SARC Studies & Programs	Presenters (bolded)
	Structure:	
	○ Overview: SARC Committees & Int'l Collaborations	Scott Okuno MD (SARC CMO; Mayo Clinic)
	▪ Spotlight: Clinical Trials Development Committee	<i>Chair: Gregory Cote MD PhD</i> (MGH) &
	▪ Concepts, Pipeline, Investigator Engagement	<i>Vice Chair: Elizabeth Davis MD</i> (VUMC)
	New Program Announcements:	
	○ Sarcoma Symposia	Steven Young & Arun Singh MD (UCLA)
	○ SARC_{TALK} Podcasts	Scott Okuno MD & Daphne Edgren (Harvard)
	NextGen Advisory Board	Ann Graham (MiB Agents) & AYA OST Survivors
	Clinical Trials Updates:	
	○ <u>Open/Actively Accruing</u>	
	▪ SARC045 Ph II Tebentafusp in Advanced CCS 	Sandra D'Angelo MD (MSKCC) &
	▪ SARC046 Ph II Nab-Sirrolimus in EHE 	Andrea Napolitano MD PhD (RMH)
	○ <u>Open/Accrual Completed</u>	Michael Wagner MD (DFCI)
	▪ SARC041 Ph III RCT Abemaciclib vs. placebo in DDLPS 	Mark Dickson MD (MSKCC): presenting during ASCO Plenary (Hall B1, 31May, 1:39-2:13 pm CT)
	▪ SARC044 Ph II Bezuclastinib w/Sunitinib in GIST	Candace Haddox MD (DFCI)
	○ <u>Planned 2026 Launches</u>	
	▪ SARC048 Ph III Neoadjuvant Doxorubicin & Ifosfamide in STS	David Liebner MD (OSU)
	▪ SARC049 Ph II Zanzalintinib Advanced in MPNST	Vanessa Eulo MD (UAB) &
		Angela Hirbe MD PhD (WashU)
11:40-11:55 am	Session 3: Keynote	
	<i>Introduction</i>	Steven Young
	<i>Keynote Speaker</i>	Brandi Benson (Author, Sarcoma Survivor, Veteran)
11:55 am-12:00 pm	Closing Remarks & Adjourn	

THANK YOU TO OUR SPONSORS SUPPORTING THE 2026 SARC SEMIANNUAL MEETING BEFORE ASCO

Platinum Sponsors



Gold Sponsors



Silver Sponsors



Bronze Sponsor

IMMUNOCORE